Webinar | If Everyone Has AI, Who Wins SEP Licensing!
3 September | 12:00 PM to 1:00 PM ET: Register Now

Thryv Therapeutics

Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
2019
11-50
Laval, Quebec, Canada
  • Cardiac (Heart Valves)
  • Drug Discovery and Development
  • Personalized Medicine Technologies

Investment Funding

Last Funding Stage

Convertible Note

Total Funding Amount

40.38M

Last Funding Amount

5.M

Last Funding Date

06-06-2023

Lead Investors

Fonds de solidarité FTQ, Lumira Ventures, Amplitude Venture Capital, Alexandria Venture Investments, Investissement Quebec

People

Founders

About

Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventricular arrhythmias. Click below to learn more about our programs.

Something missing or incorrect on this page? Help us enrich this information